On Feb. 24, 2022, BioNTech announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency had issued a positive opinion on the administration of the companies’ COVID-19 vaccine COMIRNATY as a booster dose (30ug) at least six months after the second dose in adolescents 12 through 17 years of age.

The European Commission reviewed the CHMP recommendation and was expected to make a final decision on a variation to the Conditional Marketing Authorization in the near future. If the EC grants the variation, the decision will be immediately applicable to all 27 EU member states, making booster vaccines available to everyone 12 years and older.